Literature DB >> 30694268

Janus nanoparticles in cancer diagnosis, therapy and theranostics.

Yifan Zhang1, Kai Huang, Jing Lin, Peng Huang.   

Abstract

Anisotropic Janus nanoparticles (JNPs), due to their several distinct merits, have been widely investigated for cancer theranostics. Firstly, the asymmetric modification of JNPs allows the independent release of multiple drugs. Secondly, the spatial separation of imaging materials effectively diminishes the signal interference and attenuation that usually take place in core-shell or alloy nanoparticles. Thirdly, their asymmetric composition contributes to the photothermal or potential gradient that could drive the motion of JNPs for dynamic drug delivery. This review focuses on the state-of-the-art progress of JNPs for cancer theranostics, including their categorization, fabrication strategies, and biomedical applications in cancer theranostics. The performances of JNPs and conventional core-shell nanoparticles are compared. Last but not least, the challenges and opportunities of JNPs in cancer theranostics are also discussed.

Entities:  

Mesh:

Year:  2019        PMID: 30694268     DOI: 10.1039/c8bm01523f

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  4 in total

Review 1.  Microfluidic Methods in Janus Particle Synthesis.

Authors:  Muhammad Saqib; Phong A Tran; Batur Ercan; E Yegan Erdem
Journal:  Int J Nanomedicine       Date:  2022-09-19

Review 2.  Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.

Authors:  Seungho Lim; Jooho Park; Man Kyu Shim; Wooram Um; Hong Yeol Yoon; Ju Hee Ryu; Dong-Kwon Lim; Kwangmeyung Kim
Journal:  Theranostics       Date:  2019-10-16       Impact factor: 11.556

3.  Biofunctional Janus particles promote phagocytosis of tumor cells by macrophages.

Authors:  Ya-Ru Zhang; Jia-Qi Luo; Jia-Xian Li; Qiu-Yue Huang; Xiao-Xiao Shi; Yong-Cong Huang; Kam W Leong; Wei-Ling He; Jin-Zhi Du
Journal:  Chem Sci       Date:  2020-05-05       Impact factor: 9.969

Review 4.  Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.

Authors:  Joydeb Majumder; Tamara Minko
Journal:  Adv Ther (Weinh)       Date:  2020-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.